Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease.
Jonathan S VogelgsangNiels HansenMelina StarkMichael WagnerHans KlafkiBarbara Marcos MorgadoAnke Jahn-BrodmannBjörn SchottHermann EsselmannChris BauerJohannes SchuchhardtLuca KleineidamSteffen WolfsgruberOliver PetersLuisa-Sophie SchneiderXiao WangFelix MenneJosef PrillerEike SpruthSlawek AltensteinAndrea LohseAnja SchneiderKlaus FliessbachIna VogtClaudia BartelsFrank JessenAyda RostamzadehEmrah DuezelWenzel GlanzEnise IncesoyMichaela ButrynKatharina BuergerDaniel JanowitzMichael EwersRobert PerneczkyBoris RauchmannSelim GuerselStefan TeipelIngo KilimannDoreen GoerssChristoph LaskeMatthias MunkCarolin SanzenbacherAnnika SpottkeNina Roy-KluthMichael HenekaFrederic BrosseronAlfredo RamierezMatthias SchmidJens WiltfangPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2024)
New plasma Aβ42/Aβ40 measurement using immunoprecipitation-immunoassay Plasma Aβ42/Aβ40 associated with longitudinal cognitive decline Promising biomarker to detect subjective cognitive decline at-risk for brain amyloid positivity.